CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Zacks.com on MSN3d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
GlobalData on MSN4d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trialThe Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Amitabh Bachchan’s character to play a more significant role in the sequel. The megastar will return to the sets in May to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback